Heart valve trouble? a diabetes drug may shield the heart muscle — trial puts it to the test
NCT ID NCT06469645
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial tests whether empagliflozin, a drug already used for diabetes and heart failure, can prevent the heart muscle from thickening or developing fibrosis in people with moderate aortic stenosis. Participants will receive either empagliflozin or standard care for six months, with heart changes tracked by MRI and echocardiography. The goal is to see if this medication can ease the extra strain on the heart caused by a narrowed aortic valve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- empagliflozin 10 mg once daily
- What this could lead to
- If it works, this could point toward a medication that slows or prevents heart muscle thickening and fibrosis in aortic stenosis, potentially reducing the need for surgery.
- What could go wrong
- This is a mid-stage trial with 104 participants, so results may not apply broadly. SGLT2 inhibitors can cause side effects like dehydration, urinary infections, or rare cases of diabetic ketoacidosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE AORTIC VALVE STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Norfolk and Norwich University Hospital
Norwich, Norfolk, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.